iBio (IBIO) Income from Discontinued Operations (2021 - 2024)

iBio (IBIO) has reported Income from Discontinued Operations for 4 consecutive years, with -$4.5 million the latest figure, recorded in Q2 2024.

• On a quarterly basis, Income from Discontinued Operations fell 311.63% year-over-year to -$4.5 million in Q2 2024; TTM through Jun 2024 was -$9.5 million, a 73.49% increase from a year earlier, with the FY2024 full-year figure at -$9.5 million, up 73.49% from the prior year.
• Income from Discontinued Operations was -$4.5 million for Q2 2024 at iBio, down from -$537000.0 in the prior quarter.
• Over five years, Income from Discontinued Operations peaked at -$537000.0 in Q1 2024 and troughed at -$23.0 million in Q4 2022.
• A 4-year average of -$5.5 million and a median of -$4.1 million in 2021 frame the typical range for Income from Discontinued Operations.
• Across the five-year window, Income from Discontinued Operations plunged 386.15% in 2022 and jumped 93.66% in 2023, its largest moves.
• Over 4 years, Income from Discontinued Operations stood at -$4.7 million in 2021, then sank by 386.15% to -$23.0 million in 2022, then soared by 83.81% to -$3.7 million in 2023, then declined by 21.73% to -$4.5 million in 2024.
• The last three Income from Discontinued Operations figures came in at -$4.5 million (Q2 2024), -$537000.0 (Q1 2024), and -$3.7 million (Q4 2023), per Business Quant data.